JP2010506942A5 - - Google Patents

Download PDF

Info

Publication number
JP2010506942A5
JP2010506942A5 JP2009533425A JP2009533425A JP2010506942A5 JP 2010506942 A5 JP2010506942 A5 JP 2010506942A5 JP 2009533425 A JP2009533425 A JP 2009533425A JP 2009533425 A JP2009533425 A JP 2009533425A JP 2010506942 A5 JP2010506942 A5 JP 2010506942A5
Authority
JP
Japan
Prior art keywords
alkyl
cyclodextrin
composition
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009533425A
Other languages
English (en)
Other versions
JP2010506942A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/080150 external-priority patent/WO2008067027A2/en
Publication of JP2010506942A publication Critical patent/JP2010506942A/ja
Publication of JP2010506942A5 publication Critical patent/JP2010506942A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. (a)以下の構造式で表される、少なくとも1つの、Chk1の阻害が可能な二置換尿素化合物
    Figure 2010506942
    (式中、R39はハロ、C1−3アルキル、CNまたはCFであり、
    40は水素、C1−3アルキル、CN、OC1−3アルキル、ハロ又はN(R45であり、ここで各R45は各々独立に水素又はC1−3アルキルであり、
    41は、1つのN−R44基と、さらにもう一つのN−R44基、酸素原子若しくは硫黄原子のいずれかを環に含んでいる6又は7員の飽和複素環であり、各R44は各々独立に水素原子、C1−3アルキル、CHCN又はCHCHCNであり、及びR41は場合によりオキソで置換されていてもよく、
    42は水素、C1−3アルキル、OC1−3アルキル、SC1−3アルキル、N(R45、NR45C(=O)C1−3アルキル、又は1つのN−R44基を含み場合により1〜3個のC1−3アルキルで置換された5若しくは6員の飽和複素環基であるか、
    又は、R40及びR42が、それらが結合する炭素原子と共に5〜7員の飽和炭素環を形成し、
    43は水素又はハロであり、
    但しR40及びR42のうち少なくとも1つは水素ではなく、R43がハロであるとき、R40又はR42は水素原子である)
    又はその薬理学的に許容できる塩、プロドラッグ、水和物若しくは溶媒和物、および
    (b)少なくとも1つのシクロデキストリン
    を含んでなる組成物。
  2. 前記少なくとも1つのシクロデキストリンが、スルホブチルエーテル−1−β−シクロデキストリン、スルホブチルエーテル−4−β−シクロデキストリン、スルホブチルエーテル−7−β−シクロデキストリン、ヒドロキシプロピルエーテルβ−シクロデキストリン又はその混合物を含んでなる、請求項1記載の組成物。
  3. 前記少なくとも1つのシクロデキストリンが、スルホブチルエーテル−7−β−シクロデキストリンを含んでなる、請求項2記載の組成物。
  4. 前記少なくとも1つの二置換尿素化合物が、以下の構造で表される化合物
    Figure 2010506942
    又はその薬理学的に許容できる塩、プロドラッグ、水和物若しくは溶媒和物を含んでなる、請求項3記載の組成物。
  5. pH調整剤を更に含んでなる、請求項4記載の組成物。
  6. 水溶液中で約4〜約5のpHを有する、請求項4記載の組成物。
  7. 組成物が凍結乾燥されている、請求項4記載の組成物。
  8. 以下の構造
    Figure 2010506942
    で表されChk1を阻害可能な少なくとも1つの二置換尿素化合物と、少なくとも1つのシクロデキストリンとを含んでなる組成物の、異常な細胞増殖を伴う障害の治療のための医薬の製造のための使用。
  9. 前記治療がChk1活性化剤の投与を更に含んでなる、請求項8記載の使用。
  10. 前記Chk1活性化剤が、ペメトレキセド、ゲムシタビン、シスプラチン、メトトレキサート、トリメトレキセート及びそれらの混合物からなる群から選択される、請求項9記載の使用。
JP2009533425A 2006-10-20 2007-10-02 Chk1阻害剤の組成物 Pending JP2010506942A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85305606P 2006-10-20 2006-10-20
PCT/US2007/080150 WO2008067027A2 (en) 2006-10-20 2007-10-02 Compositions of chkl inhibitors and cyclodextrin

Publications (2)

Publication Number Publication Date
JP2010506942A JP2010506942A (ja) 2010-03-04
JP2010506942A5 true JP2010506942A5 (ja) 2010-11-18

Family

ID=39338658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533425A Pending JP2010506942A (ja) 2006-10-20 2007-10-02 Chk1阻害剤の組成物

Country Status (22)

Country Link
US (1) US8455471B2 (ja)
EP (1) EP2063879A2 (ja)
JP (1) JP2010506942A (ja)
KR (2) KR20090065537A (ja)
CN (1) CN101528215B (ja)
AU (1) AU2007325576B2 (ja)
BR (1) BRPI0717460A2 (ja)
CA (1) CA2673483C (ja)
CO (1) CO6180503A2 (ja)
CR (1) CR10680A (ja)
EA (1) EA200900571A1 (ja)
IL (1) IL197869A (ja)
MA (1) MA30872B1 (ja)
MX (1) MX2009004214A (ja)
MY (1) MY150649A (ja)
NO (1) NO20091544L (ja)
NZ (1) NZ575394A (ja)
SV (1) SV2009003227A (ja)
TN (1) TN2009000146A1 (ja)
UA (1) UA95310C2 (ja)
WO (1) WO2008067027A2 (ja)
ZA (1) ZA200902670B (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596515A (en) 2009-05-29 2014-03-28 Cydex Pharmaceuticals Inc Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
GB201008005D0 (en) 2010-05-13 2010-06-30 Sentinel Oncology Ltd Pharmaceutical compounds
PL2758052T3 (pl) * 2011-09-18 2018-10-31 Euro-Celtique S.A. Kompozycja farmaceutyczna zawierająca inhibitor HDAC i cyklopolisacharyd
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
US9108950B2 (en) 2011-10-03 2015-08-18 Respivert, Ltd. 1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
MX2020000205A (es) 2012-04-13 2022-06-06 L&F Res Llc Metodo para utilizar ciclodextrina.
EP3024457A4 (en) 2013-07-26 2017-06-28 Update Pharma Inc. Compositions to improve the therapeutic benefit of bisantrene
JP6630280B2 (ja) 2014-02-14 2020-01-15 レスピバート・リミテツド 抗炎症化合物としての芳香族複素環化合物
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US9890564B2 (en) * 2014-10-28 2018-02-13 Sargent Manufacturing Company Interconnected lock with direct drive for adjustable deadbolt to latchbolt spacing
JP2017155023A (ja) * 2016-03-04 2017-09-07 ジェイファーマ株式会社 Lat1阻害活性を有する芳香族アミノ酸誘導体を含有する注射剤
WO2017163128A2 (en) * 2016-03-20 2017-09-28 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
AU2018341235A1 (en) 2017-09-28 2020-05-07 Asdera Llc Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation
CN109078005B (zh) * 2018-08-07 2021-11-26 江苏领航生物科技有限公司 一种白消安组合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
HU193933B (en) 1984-06-08 1987-12-28 Nitrokemia Ipartelepek Herbicide or plant growth stimulating agent comprising beta-cyclodextrin complex of benzolsulphonylurea derivative and process for preparing the active substances
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9001987D0 (en) 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
AU759280C (en) * 1998-02-23 2004-01-22 Cyclops, Ehf High-energy cyclodextrin complexes
US6565880B2 (en) 2000-07-24 2003-05-20 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
WO2003015828A1 (en) 2001-08-20 2003-02-27 Boehringer Ingelheim Pharmaceuticals, Inc. Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and a cyclodextrin
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
KR20070064414A (ko) * 2003-09-17 2007-06-20 이코스 코포레이션 세포 증식 제어를 위한 chk1 억제제의 용도
KR20050039573A (ko) * 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
US8093244B2 (en) 2005-03-29 2012-01-10 Icos Corporation Heteroaryl urea derivatives useful for inhibiting CHK1
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂

Similar Documents

Publication Publication Date Title
JP2010506942A5 (ja)
JP2015143283A5 (ja)
JP2018511647A5 (ja)
TW200716528A (en) Cyclopropanecarboxamide derivatives
JP2009526034A5 (ja)
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
MX2009003958A (es) Nuevos derivados de 1,4-benzotiepina-1,1-dioxido sustituidos con radicales bencilo, metodo para su preparacion, productos farmaceuticos que comprenden estos compuestos y su uso.
ECSP055867A (es) Derivados de pirrolopirimidina
TW200628154A (en) Organic compounds
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
JP2011504903A5 (ja)
TW200643013A (en) Pyrazoles
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
RU2011137531A (ru) Новое производное триазина и содержащая его фармацевтическая композиция
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
JP2008545718A5 (ja)
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
AU2019201104B2 (en) Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression and neuropathic pain
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
TW200637817A (en) 5-aminoindole derivatives
ES2374017T3 (es) Agentes terapéuticos útiles para el tratamiento del dolor.
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
RU2011134283A (ru) Имидазотиазольные производные, имеющие пролиновую циклическую структуру